(Albany, US) September 10, 2026- DelveInsight’s “Graft versus host disease Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Graft versus host disease (GVHD) pipeline landscape. It covers the GVHD pipeline drug profiles, including clinical and nonclinical stage products. It also covers the GVHD pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Graft Versus Host Disease Treatment Landscape @ https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight
Key Takeaways from the Graft Versus Host Disease Pipeline Report
DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for GVHD treatment.
The leading Graft Versus Host Disease Companies include Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, and others.
Promising Graft Versus Host Disease Pipeline Therapies such as Itolizumab, ABSK021 (Pimicotinib), SYN-004 (ribaxamase), SER-155, T-Guard, MaaT013, Axatilimab, TQ 05105, and others.
The GVHD companies which have their drug candidates in the most advanced stage, i.e. Phase III, include Equillium, Biocon, Xenikos, and MaaT Pharma.
Gain in-depth knowledge of key Graft Versus Host Disease clinical trials, emerging drugs, and market opportunities @ Graft Versus Host Disease Clinical Trials Assessment
Graft Versus Host Disease Overview
Graft versus host disease (GVHD) is a serious complication that occurs when donor immune cells attack the recipient’s body following an allogeneic stem cell or bone marrow transplant. The condition arises because the donor’s immune cells recognize the recipient’s cells as foreign and mount an immune response against them, with donor T-cells from the graft primarily driving the disease. GVHD is classified into two main types: acute, which typically develops within the first 100 days post-transplant and presents through skin rashes, jaundice, liver enzyme abnormalities, and diarrhea; and chronic, which occurs after 100 days and can affect multiple organs, producing symptoms such as skin thickening, joint contractures, dry eyes, and lung dysfunction.
The risk of developing GVHD is shaped by several factors, including the degree of HLA matching between donor and recipient, the type of donor, and the recipient’s age. Mismatched HLA substantially raises the risk, as does the use of unrelated or haploidentical donors and cord blood transplants relative to matched sibling donors, while older recipients and more intensive pre-transplant conditioning regimens further increase susceptibility. Diagnosis relies on clinical presentation, biopsy of affected tissues, and exclusion of other potential causes of the symptoms.
Preventive management of GVHD centers on prophylactic immunosuppressive therapies such as cyclosporine, tacrolimus, methotrexate, and mycophenolate mofetil. Acute GVHD is generally treated with high-dose corticosteroids, with agents like ruxolitinib and antithymocyte globulin (ATG) reserved for steroid-refractory cases, while chronic GVHD treatment includes corticosteroids and calcineurin inhibitors alongside newer therapies such as ibrutinib and ruxolitinib for refractory disease. Despite these options, GVHD continues to drive significant morbidity and mortality through direct organ damage and heightened infection risk from prolonged immunosuppression.
Prognosis varies widely: acute GVHD carries an immediate risk of severe outcomes, while chronic GVHD can lead to long-term health complications, including chronic infections, secondary cancers, and debilitating organ dysfunction. Ongoing research into the mechanisms underlying GVHD, along with advances in immunotherapy and personalized medicine, continues to shape more targeted therapies aimed at reducing the incidence and severity of the disease and improving transplant outcomes.
Graft Versus Host Disease Emerging Drugs Profile
Itolizumab: Equillium Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of T cells driving a number of immuno-inflammatory diseases. Itolizumab was launched in India in 2013 under the brand name ALZUMAB and received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome. The drug is currently in Phase III clinical development for the treatment of acute graft-versus-host disease (aGVHD).
ABSK021 (Pimicotinib): Abbisko Therapeutics Pimicotinib (ABSK021) is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R, independently developed by Abbisko Therapeutics. Abbisko is also exploring pimicotinib’s potential in other indications, including several types of solid tumors, and has obtained NMPA approval to conduct a Phase II clinical study in chronic graft-versus-host disease. Currently, the drug is in the Phase II stage of its development for the treatment of Chronic Graft Versus Host Disease.
SYN-004 (ribaxamase): Theriva Biologics SYN-004 is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract, helping maintain the natural balance of the gut microbiome for acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Because allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection, antibiotic-mediated damage of the gut microbiome has been strongly associated with adverse outcomes including CDI, vancomycin-resistant enterococci (VRE) colonization, potentially fatal bacteremia, and aGVHD. Currently, the drug is in the Phase I/II stage of its development for the treatment of Graft versus host disease.
SER-155: Seres Therapeutics SER-155 is an oral, investigational therapeutic comprising a fermented consortium of commensal bacteria, specifically designed to support immunocompromised patients. Its primary mechanism of action involves augmenting crucial microbiome functions that contribute to improved survival and reduced risks of infections and GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the aim of fortifying the gut microbiome, enhancing immune function, and protecting against gastrointestinal infections and bacteremia. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of GvHD.
The Graft Versus Host Disease Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Graft versus host disease (GVHD), with aggregate therapies developed by each company.
It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for GVHD treatment.
GVHD Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
GVHD drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the GVHD market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Graft Versus Host Disease Unmet Needs
Graft Versus Host Disease Companies
Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, and others.
GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Graft versus host disease products have been categorized under various ROAs such as:
Intravenous
Subcutaneous
Oral
Intramuscular
Rectal
Graft Versus Host Disease Products have been categorized under various Molecule types such as:
Monoclonal antibody
Small molecule
Peptide
Selected GVHD Pipeline Drugs at a Glance
Itolizumab: Biocon | Phase III | CD6 antigen inhibitors | Intravenous
T-Guard: Xenikos | Phase III | T lymphocyte inhibitors; Protein synthesis inhibitors | Intravenous
MaaT013: MaaT Pharma | Phase III | Bacteria replacements; Gastrointestinal microbiome modulators | Rectal
Axatilimab: Syndax Pharmaceuticals | Phase II | Macrophage colony stimulating factor receptor antagonists | Intravenous
TQ 05105: Chia Tai Tianqing Pharmaceutical Group | Phase I/II | Janus kinase-2 inhibitors | Oral
Transform your understanding of the Graft Versus Host Disease Pipeline! @ Graft Versus Host Disease Market
Scope of the Graft Versus Host Disease Pipeline Report
Coverage- Global
Graft Versus Host Disease Companies- Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen and others.
Graft Versus Host Disease Pipeline Therapies- Itolizumab, ABSK021 (Pimicotinib), SYN-004 (ribaxamase), SER-155, T-Guard, MaaT013, Axatilimab, TQ 05105 and others.
Graft Versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Graft Versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Graft Versus Host Disease Pipeline Analysis Today! @ Graft Versus Host Disease Drugs and Companies
Table of Contents
Introduction
Executive Summary
Graft versus Host Disease: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Graft versus Host Disease: DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Graft versus Host Disease Key Companies
Graft versus Host Disease Key Products
Graft versus Host Disease: Unmet Needs
Graft versus Host Disease: Market Drivers and Barriers
Graft versus Host Disease: Future Perspectives and Conclusion
Graft versus Host Disease Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight
